The following represents selected information for the Companys reportable segments for the three and six months ended June 30, 2019 and 2018 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Net revenues from external customers: Branded Pharmaceuticals $ 209,013 $ 212,637 $ 412,538 $ 412,872 Sterile Injectables 244,280 217,843 514,328 433,697 Generic Pharmaceuticals 217,784 241,236 436,310 490,476 International Pharmaceuticals (1) 28,650 42,980 56,962 78,178 Total net revenues from external customers $ 699,727 $ 714,696 $ 1,420,138 $ 1,415,223 Adjusted income from continuing operations before income tax: Branded Pharmaceuticals $ 82,965 $ 83,749 $ 161,973 $ 177,563 Sterile Injectables 172,188 173,308 368,371 342,753 Generic Pharmaceuticals 49,308 90,302 99,305 164,582 International Pharmaceuticals 11,447 18,499 23,542 32,217 Total segment adjusted income from continuing operations before income tax $ 315,908 $ 365,858 $ 653,191 $ 717,115 __________ (1) Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada. The table below provides reconciliations of our Total consolidated loss from continuing operations before income tax , which is determined in accordance with U.S. GAAP, to our total segment adjusted income from continuing operations before income tax for the three and six months ended June 30, 2019 and 2018 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Total consolidated loss from continuing operations before income tax $ (94,584 ) $ (46,244 ) $ (96,293 ) $ (528,491 ) Interest expense, net 134,809 130,059 267,484 254,049 Corporate unallocated costs (1) 38,365 43,046 86,460 95,506 Amortization of intangible assets 140,418 153,215 286,017 310,387 Inventory step-up  124  190 Upfront and milestone payments to partners 1,444 36,964 2,383 38,296 Separation benefits and other cost reduction initiatives (2) 2,124 29,153 4,149 78,140 Certain litigation-related and other contingencies, net (3) 10,315 19,620 10,321 17,120 Asset impairment charges (4) 88,438 22,767 253,886 471,183 Acquisition-related and integration items (5) (5,507 ) 5,161 (43,008 ) 11,996 Gain on extinguishment of debt   (119,828 )  Foreign currency impact related to the remeasurement of intercompany debt instruments 2,262 (574 ) 3,796 (3,088 ) Other, net (6) (2,176 ) (27,433 ) (2,176 ) (28,173 ) Total segment adjusted income from continuing operations before income tax $ 315,908 $ 365,858 $ 653,191 $ 717,115 __________ (1) Amounts include certain corporate overhead costs, such as headcount, facility and corporate litigation expenses and certain other income and expenses. (2) Amounts for the three and six months ended June 30, 2019 primarily relate to employee separation costs of $0.4 million and $2.2 million , respectively, and other charges of $1.7 million and $1.9 million , respectively. Amounts for the three and six months ended June 30, 2018 primarily relate to employee separation costs of $5.4 million and $30.6 million , respectively, accelerated depreciation of $18.1 million and $35.2 million , respectively, charges to increase excess inventory reserves of $0.2 million and $2.6 million , respectively, and other charges of $5.4 million and $9.7 million , respectively. These charges were related primarily to our restructuring initiatives. See Note 4. Restructuring for discussion of our material restructuring initiatives. (3) Amounts include adjustments for Litigation-related and other contingencies, net as further described in Note 13. Commitments and Contingencies . (4) Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 9. Goodwill and Other Intangibles . (5) Amounts primarily relate to changes in the fair value of contingent consideration. (6) Amounts primarily relate to gains on sales of businesses and other assets .